Reverse hydroxamate inhibitors of matrix metalloproteinases
申请人:——
公开号:US20020007060A1
公开(公告)日:2002-01-17
Compounds having the formula
1
are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.
N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES
申请人:Abbott Laboratories
公开号:EP1001930B1
公开(公告)日:2002-12-04
Biaryl Ether Retrohydroxamates as Potent, Long-lived, Orally Bioavailable MMP Inhibitors
作者:Michael R. Michaelides、Joseph F. Dellaria、Jane Gong、James H. Holms、Jennifer J. Bouska、Jamie Stacey、Carol K. Wada、H.Robin Heyman、Michael L. Curtin、Yan Guo、Carole L. Goodfellow、Ildiko B. Elmore、Daniel H. Albert、Terrance J. Magoc、Patrick A. Marcotte、Douglas W. Morgan、Steven K. Davidsen
DOI:10.1016/s0960-894x(01)00031-2
日期:2001.6
A novel series of biaryl ether reverse hydroxamate MMP inhibitors has been developed. These compounds are potent MMP-2 inhibitors with limited activity against MMP-1. Select members of this series exhibit excellent pharmacokinetic properties with long elimination half-lives (7 h) and high oral bioavailability (100%). (C) 2001 Elsevier Science Ltd. All rights reserved.